Vlad Dragan1, Yanliang Wei1, Marion Elligsen2, Alex Kiss3, Sandra A N Walker2,4, Jerome A Leis1,3,5,6. 1. Department of Medicine, University of Toronto, Ontario, Canada. 2. Department of Pharmacy, Sunnybrook Health Sciences Centre, Ontario, Canada. 3. Sunnybrook Research Institute and Institute of Health Policy, Management and Evaluation, Ontario, Canada. 4. Leslie Dan Faculty of Pharmacy, University of Toronto, Ontario, Canada. 5. Division of Infectious Diseases and General Internal Medicine, Sunnybrook Health Sciences Centre, Ontario, Canada. 6. Centre for Quality Improvement and Patient Safety, University of Toronto, Ontario, Canada.
Abstract
Background: Prophylactic antimicrobial therapy is frequently prescribed for acute aspiration pneumonitis, with the intent of preventing the development of aspiration pneumonia. However, few clinical studies have examined the benefits and harms of this practice. Methods: A retrospective cohort study design was used to compare outcomes of patients with aspiration pneumonitis who received prophylactic antimicrobial therapy with those managed with supportive care only during the initial 2 days following macroaspiration. The primary outcome was in-hospital mortality within 30 days. Secondary outcomes included transfer to critical care and antimicrobial therapy received between days 3 and 14 following macroaspiration including escalation of therapy and antibiotic-free days. Results: Among 1483 patients reviewed, 200 met the case definition for acute aspiration pneumonitis, including 76 (38%) who received prophylactic antimicrobial therapy and 124 (62%) who received supportive management only. After adjusting for patient-level predictors, antimicrobial prophylaxis was not associated with any improvement in mortality (odds ratio, 0.9; 95% confidence interval [CI], 0.4-1.7; P = .7). Patients receiving prophylactic antimicrobial therapy were no less likely to require transfer to critical care (5% vs 6%; P = .7) and subsequently received more frequent escalation of antibiotic therapy (8% vs 1%; P = .002) and fewer antibiotic-free days (7.5 vs 10.9; P < .0001). Conclusions: Prophylactic antimicrobial therapy for patients with acute aspiration pneumonitis does not offer clinical benefit and may generate antibiotic selective pressures that results in the need for escalation of antibiotic therapy among those who develop aspiration pneumonia.
Background: Prophylactic antimicrobial therapy is frequently prescribed for acute aspiration pneumonitis, with the intent of preventing the development of aspiration pneumonia. However, few clinical studies have examined the benefits and harms of this practice. Methods: A retrospective cohort study design was used to compare outcomes of patients with aspiration pneumonitis who received prophylactic antimicrobial therapy with those managed with supportive care only during the initial 2 days following macroaspiration. The primary outcome was in-hospital mortality within 30 days. Secondary outcomes included transfer to critical care and antimicrobial therapy received between days 3 and 14 following macroaspiration including escalation of therapy and antibiotic-free days. Results: Among 1483 patients reviewed, 200 met the case definition for acute aspiration pneumonitis, including 76 (38%) who received prophylactic antimicrobial therapy and 124 (62%) who received supportive management only. After adjusting for patient-level predictors, antimicrobial prophylaxis was not associated with any improvement in mortality (odds ratio, 0.9; 95% confidence interval [CI], 0.4-1.7; P = .7). Patients receiving prophylactic antimicrobial therapy were no less likely to require transfer to critical care (5% vs 6%; P = .7) and subsequently received more frequent escalation of antibiotic therapy (8% vs 1%; P = .002) and fewer antibiotic-free days (7.5 vs 10.9; P < .0001). Conclusions: Prophylactic antimicrobial therapy for patients with acute aspiration pneumonitis does not offer clinical benefit and may generate antibiotic selective pressures that results in the need for escalation of antibiotic therapy among those who develop aspiration pneumonia.
Authors: Liesbet De Bus; Bram Gadeyne; Johan Steen; Jerina Boelens; Geert Claeys; Dominique Benoit; Jan De Waele; Johan Decruyenaere; Pieter Depuydt Journal: Crit Care Date: 2018-09-29 Impact factor: 9.097
Authors: Amol A Verma; Tejasvi Hora; Hae Young Jung; Michael Fralick; Sarah L Malecki; Lauren Lapointe-Shaw; Adina Weinerman; Terence Tang; Janice L Kwan; Jessica J Liu; Shail Rawal; Timothy C Y Chan; Angela M Cheung; Laura C Rosella; Marzyeh Ghassemi; Margaret Herridge; Muhammad Mamdani; Fahad Razak Journal: CMAJ Date: 2021-02-10 Impact factor: 8.262
Authors: Jennifer Howard; Carol R Reinero; Greg Almond; Aida Vientos-Plotts; Leah A Cohn; Megan Grobman Journal: J Vet Intern Med Date: 2021-11-09 Impact factor: 3.333
Authors: Amol A Verma; Tejasvi Hora; Hae Young Jung; Michael Fralick; Sarah L Malecki; Lauren Lapointe-Shaw; Adina Weinerman; Terence Tang; Janice L Kwan; Jessica J Liu; Shail Rawal; Timothy C Y Chan; Angela M Cheung; Laura C Rosella; Marzyeh Ghassemi; Margaret Herridge; Muhammad Mamdani; Fahad Razak Journal: CMAJ Date: 2021-06-07 Impact factor: 8.262